Share-based Payment Arrangement, Expense of Milestone Pharmaceuticals Inc. from 31 Mar 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Milestone Pharmaceuticals Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2018 to 30 Sep 2025.
  • Milestone Pharmaceuticals Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,250,000, a 11% decline year-over-year.
  • Milestone Pharmaceuticals Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $5,383,000, a 13% decline year-over-year.
  • Milestone Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2024 was $5,776,000, a 39% decline from 2023.
  • Milestone Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2023 was $9,534,000, a 5.4% increase from 2022.
  • Milestone Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2022 was $9,048,000, a 24% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Milestone Pharmaceuticals Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $5,383,000 $1,250,000 -$149,000 -11% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $5,532,000 $1,308,000 -$83,000 -6% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $5,615,000 $1,351,000 -$161,000 -11% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $5,776,000 $1,474,000 -$403,000 -21% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
Q3 2024 $6,179,000 $1,399,000 -$1,473,000 -51% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $7,652,000 $1,391,000 -$1,101,000 -44% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $8,753,000 $1,512,000 -$781,000 -34% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $9,534,000 $1,877,000 -$266,000 -12% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $9,800,000 $2,872,000 +$492,000 +21% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $9,308,000 $2,492,000 +$81,000 +3.4% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $9,227,000 $2,293,000 +$179,000 +8.5% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $9,048,000 $2,143,000 +$168,000 +8.5% 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $8,880,000 $2,380,000 +$356,000 +18% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $8,524,000 $2,411,000 +$499,000 +26% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $8,025,000 $2,114,000 +$746,000 +55% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $7,279,000 $1,975,000 +$545,000 +38% 01 Oct 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q3 2021 $6,734,000 $2,024,000 +$681,000 +51% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $6,053,000 $1,912,000 +$721,000 +61% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $5,332,000 $1,368,000 +$387,000 +39% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $4,945,000 $1,430,000 +$1,076,000 +304% 01 Oct 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
Q3 2020 $3,869,000 $1,343,000 +$993,000 +284% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $2,876,000 $1,191,000 +$915,000 +332% 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021 2021 Q2
Q1 2020 $1,961,000 $981,000 +$770,000 +365% 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1
Q4 2019 $1,191,000 $354,000 +$11,000 +3.2% 01 Oct 2019 31 Dec 2019 10-K 29 Mar 2021 2020 FY
Q3 2019 $1,180,000 $350,000 +$265,000 +312% 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020 2020 Q3
Q2 2019 $915,000 $276,000 +$196,000 +245% 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020 2020 Q2
Q1 2019 $719,000 $211,000 +$86,000 +69% 01 Jan 2019 31 Mar 2019 10-Q 14 May 2020 2020 Q1
Q4 2018 $633,000 $343,000 01 Oct 2018 31 Dec 2018 10-K/A 23 Oct 2020 2019 FY
Q3 2018 $85,000 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019 2019 Q3
Q2 2018 $80,000 01 Apr 2018 30 Jun 2018 10-Q 13 Aug 2019 2019 Q2
Q1 2018 $125,000 01 Jan 2018 31 Mar 2018 10-Q 19 Jun 2019 2019 Q1

Milestone Pharmaceuticals Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $5,776,000 -$3,758,000 -39% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
2023 $9,534,000 +$486,000 +5.4% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $9,048,000 +$1,769,000 +24% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $7,279,000 +$2,334,000 +47% 01 Jan 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
2020 $4,945,000 +$3,754,000 +315% 01 Jan 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
2019 $1,191,000 +$558,000 +88% 01 Jan 2019 31 Dec 2019 10-K 29 Mar 2021 2020 FY
2018 $633,000 01 Jan 2018 31 Dec 2018 10-K/A 23 Oct 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.